VivoSeq
Cardiovascular

Cardiac Sarcoidosis

13

Pipeline Programs↗

5

Active Trials↗

9

Companies Involved↗

Cardiac Sarcoidosis is an emerging landscape with 13 programs across 9 companies. The most active players are Kiniksa Pharmaceuticals (UK), Ltd., Eli Lilly, Navidea Biopharmaceuticals. 1 therapy is approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

11/100

Mech. Concentration

29/100

Completion Rate

60/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kiniksa Pharmaceuticals (UK), Ltd.

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2N

Navidea Biopharmaceuticals

1 program

Phase 2Takeda logo

Takeda

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

62%

Small molecule

8 of 13 classified programs — the dominant modality here.

38%ALL OTHERSProtein / enzyme215%Radiopharmaceutical215%Monoclonal antibody18%

Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 100% of 14 pipeline programs.

Analysis

Trial Status

15

clinical trials

Completed6 · 40%
Recruiting4 · 27%
Withdrawn2 · 13%
Terminated2 · 13%
Not yet recruiting1 · 7%

Clinical Trials

Trial Activity

15 trials

Rilonacept in Subjects With Cardiac Sarcoidosis
Recruiting·MMayo Clinic·Phase 2·NCT06660732·60 enrolled
Repurposing Tilmanocept for Cardiac Sarcoidosis
Recruiting·—·Phase 2·NCT07159074·15 enrolled
Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial
Recruiting·OOttawa Heart Institute Research Corporation·Phase 3·NCT03593759·160 enrolled
Cardiac Sarcoidosis Multi-Center Prospective Cohort Study
Recruiting·OOttawa Heart Institute Research Corporation·N/A·NCT01477359·1,500 enrolled
A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
Not yet recruiting·SStanford University·Phase 2·NCT06868381·10 enrolled
PET Imaging in Patients With Suspected Cardiac Sarcoidosis
Completed·UUniversity of Pennsylvania·N/A·NCT03746847·20 enrolled
Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis
Completed·VVirginia Commonwealth University·Phase 2·NCT04017936·17 enrolled
Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac Sarcoidosis
Completed·—·N/A·NCT04206163·78 enrolled
Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
Completed·MMarcelo F. Di Carli, MD, FACC·N/A·NCT02546388·17 enrolled
d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis
Completed·MMayo Clinic·Phase 4·NCT03549598·15 enrolled
PET/MR Imaging In Patients With Cardiac Sarcoidosis
Completed·UUniversity of Edinburgh·N/A·NCT03705884·40 enrolled
18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation
Terminated·SStanford University·Phase 2·NCT03103490·45 enrolled
A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis
Terminated·KKinevant Sciences GmbH·Phase 2·NCT05351554·1 enrolled
Somatostatin Receptor Imaging in Cardiac Sarcoidosis
Withdrawn·—·N/A·NCT02812849
Cardiac Sarcoidosis Response To Steroids Trial
Withdrawn·OOttawa Heart Institute Research Corporation·Phase 4·NCT01210677

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)